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Introduction: Drug transporters are large transmembrane proteins which
catalyse the movement of a wide variety of chemicals, including drugs as
10well as xeno- and endobiotics through cellular membranes. The major groups
of these proteins include the ATP- binding cassette transporters which in
eukaryotes work as ATP-fuelled drug ‘exporters’ and the Solute Carrier 
transporters, with various transport directions and mechanisms.
Areas covered: In this review, we discuss the key ATP-binding cassette and
15Solute Carrier drug transporters which have been reported to contribute to
the function and/or protection of undifferentiated human stem cells and
during tissue differentiation. We review the various techniques for studying
transporter expression and function in stem cells, and the role of drug
transporters in foetal and placental tissues is also discussed. We especially
20focus on the regulation of transporter expression by factors modulating cell
differentiation properties and on the function of the transporters in adjust-
ment to environmental challenges.
Expert opinion: The relatively new and as yet unexplored territory of trans-
porters in stem cell biology may rapidly expand and bring important new
25information regarding the metabolic and epigenetic regulation of ‘stemness’
and the early differentiation properties. Drug transporters are clearly impor-
tant protective and regulatory components in stem cells and differentiation.
Keywords: ABC transporters, drug transporters , human stem cell differentiation , pluripotent stem
cells, regulation of transporter expression, SLC transporters
30Expert Opin. Drug Metab. Toxicol. (2015) 00(00):1–16
1. Introduction
According to our recent understanding, most of the cellular substrates are taken
up and extruded by membrane-bound transporter proteins, while passive diffusion
35through the cell membrane has a relatively limited role in these processes. However,
hydrophobic compounds, including drugs, may rapidly enter the cell membrane by
diffusion, and specific protective transporters are required to preserve cell integrity
against such agents. Drug and xenobiotic transporters are large transmembrane
proteins which catalyse the movement of a wide variety of chemicals, including
40drugs, as well as xeno- and endobiotics through cellular membranes. The major
groups of these proteins include the ATP- binding cassette (ABC) transporters
which in eukaryotes work as ATP-fuelled drug ‘exporters’ and the Solute Carrier
(SLC) transporters, with various transport directions and mechanisms.
In this review, we summarize the recent knowledge about the ABC and SLC
45drug transporters in human pluripotent stem cells which are one of the most
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promising sources for cell therapy in the future. As detailed
in this paper, the techniques for accurately measuring the
expression, localization and function of drug transporters in
stem cells may require special considerations, since in many
50 cases, the relatively low levels of a selected transporter may be
fundamentally important under various stages of human cell
differentiation. A major part of this review is focusing on the
presentation of the somewhat contradictory results concerning
ABC transporter expression, highlighting the expression and
55 role of the ABCG2 multidrug transporter, which seems to
have an important protective effect in the undifferentiated
stem cells, but also has a greatly variable expression during
further tissue differentiation. In another section, we review the
relatively small and scattered amount of data regarding SLC
60 transporter expression and function in stem cells. In this case,
we know a lot more about the function of these transporters in
the placenta and in the differentiated tissues, while a thorough
examination of the SLC transporter expression pattern in the
undifferentiated human stem cells is still missing.
65 In the final section of this review, we discuss the regulatory
pathways modulating xenobiotic transporter expression
during the pluripotent state and early differentiation.
Interestingly, several complex pathways, from the regulation
of transcription, translation and the post-translational mod-
70 ifications, significantly affect drug transporter expression and
localization. We feel that covering this relatively unexplored
territory of transporters in stem cell biology may call the
attention to the metabolic and epigenetic regulation of ‘stem-
ness’ by drugs and xenobiotics, as well as these effects on
75 early stem cell differentiation properties.
2. Techniques for studying transporter expression
in human stem cells
Drug transporters are often rapidly regulated both at the
transcriptional and translational levels to allow efficient pro-
80 tection of the cells from toxic environmental conditions [1]
or, as in the case of ABCG2, also to regulate cell cycle
progression.[2] Therefore, varying levels of protein expression
can be expected not only at the population level, but even
when following a single cell in time. Accordingly, the assays
85 used for studying transporter expression should be sensitive
enough to detect even low endogenous expression levels. In
addition, examinations – whenever possible – should target
both the mRNA and the protein expression levels and pre-
ferably also assess the functionality of the transporters.
90 Most of the techniques for studying transporter expression
in human stem cells were taken over from the field of cancer
research, studying ABC transporter-mediated multidrug
resistance (MDR) in cancerous tissues or cell lines.
Heterogeneous and low-level expression of transporters
95 found in clinical samples called long ago for standardization
of the measurement techniques.[3] However, in spite of the
various measuring techniques accumulated over the decades
in this field, some problems in the proper assessment of
transporter expression are still present in the area of human
100stem cell research.
An example for these controversial findings is the case of
ABCG2 multidrug transporter expression in hPSCs. Previous
findings showed that ABCG2 expression is a conserved fea-
ture of tissue stem cells in the bone marrow and in many
105other solid organs [4,5]; therefore, the question arose whether
hPSCs express this transporter. Several different answers were
provided, ranging from no expression [6] to the detection of
ABCG2 mRNA and its translation to functional protein [7]
(more on this topic in Section 3). Several explanations were
110suggested to resolve these differences, for example that insuf-
ficient culture condition might promote expression of the
functional ABCG2 transporter or that a long 3
0
 -untranslated
regions (UTR) variant of the ABCG2 mRNA might be a
target for miRNA-based repression of translation, as found in
115some hESC lines.[8] In addition to potential biological
causes, technical issues might also play a role in the described
phenomenon. Cancer cell lines usually extremely overexpress
the MDR transporters as a result of long-term drug selection
or artificial gene delivery; therefore, techniques detecting
120transporter expression in these types of systems may fail to
be sensitive enough to detect low levels of endogenous trans-
porter expression, possibly occurring in hPSCs.
In this part of the review, we summarize the most relevant
techniques and share our experience regarding the pitfalls of
125studying transporter expression in human stem cells and how
to avoid them. We also emphasize that standardization of
protein detection protocols – especially in the case of
ABCG2, where function-dependent conformational changes
of the ABCG2 can modify its interaction with the often used
130monoclonal antibody [9,10] – should provide more compar-
able results. After this standardization, the involvement of
specific biological mechanisms can be properly explored, even
considering the potential cell line or culture condition
differences .
1352.1. Studying transporter expression at the mRNA level
Several methods allow the detection of transporter mRNA
expression levels including microarrays and quantitative real
time PCR (qRT-PCR) measurements, as elegantly reviewed
by Gillet et al. [11]. These methods are especially relevant
140when a wide range of transporter expression profile of the
cells has to be examined, since detection of numerous human
transporters at the protein level is hindered by the lack of
reliable antibodies. However, the sensitivity of these methods
varies as the extensive comparison by Gillet and colleagues
145showed.[11,12] While microarrays proved to be less adequate
to discriminate between products of highly homologous
genes, the Human ABC Transporter TaqMan Low-Density
Array (TLDA) has been documented to be most sensitive
and best suited for accurately quantitating individual ABC
150transporter genes in a high-throughput format.[11,12] 
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Therefore, when assessing the transporter profile of hPSCs
and early derivatives, currently the TLDA should be the
method of choice.[13]
ABC transporter mRNA levels significantly change over
155 the course of hPSC differentiation [13,14]; therefore, parallel
to the examination of transporter profiles, a pluripotency
array analysis should also be performed to validate the plur-
ipotent state of the hPSCs. Pluripotency arrays usually con-
tain pluripotency and lineage-specific markers, allowing the
160 identification of hPSCs as pluripotency-positive/lineage-
negative cells and also their differentiated progenies, becom-
ing pluripotency negative/lineage positive. Thus, characteris-
tic transporter mRNA expression patterns for different cell
types at various maturation stages can be investigated in an
165 isogenic system.[13,15]
Findings of Rottenberg and colleagues [16,17] indicate that
even a low-level increase in the mRNA levels of ABC trans-
porters can be relevant and translate to transporter levels which
are able to protect tumour cells against chemotherapy. In their
170 studies, drug-sensitive and drug-resistant tumour samples
showed less than 10-fold difference for ABCB1 and less than
5-fold for ABCG2 mRNA levels. As these elevations of mRNA
expression can result in biologically relevant functional mem-
brane protein expression, an important point is to follow
175 actual transporter expression, localization and function.
2.2. Studying transporter protein expression and
localization
The currently employed key techniques in this regard involve
immunocytochemistry and flow cytometry analysis.
180 However, in many cases, regular fluorescence microscopy
may not be sensitive enough for the detection of low levels
of immunofluorescence, which is characteristic for the low-
level endogenous transporter expression in stem cells, as
compared to transporter overexpressing cancer cell lines.
185 Still, excitation with the adequate laser lines and detection
with photomultiplier in most cases allows the sensitive exam-
ination of immunostaining of endogenous transporters in
hPSCs. Laser-based flow cytometry measurements provide a
sensitive method for the detection of endogenously expressed,
190 immunolabelled transporters, and in addition, this method
provides quantitative results.
In addition of choosing sensitive detection systems, the
staining protocols should also be optimized for each and
every antibody and detection method. In general, to max-
195 imize signal over background ratio, a bright fluorochrome
(e.g. phycoerythrin) should be used for the secondary anti-
body labelling when antigens are expected to be represented
at low density. Whereas flow cytometry applications are less
affected, the poor photostability of phycoerythrin must be
200 considered when signal detection involves microscopy appli-
cations with high-intensity illumination, long exposure times
or repetitive image acquisition from the same area of the
sample. In addition, to increase the detection of monoclonal
primary antibodies, subclass-specific secondary antibodies
205should be preferably used.[18]
The case of ABCG2 (and the 5D3 monoclonal antibody
raised against it) is again a good example how improved
interaction between antigen and antibody can enhance the
sensitivity of detection. During the transport cycle, the con-
210formation of ABCG2 changes. In intact cells, as shown by
Özvegy-Laczka et al., the cell surface epitope recognized by
the 5D3 monoclonal antibody exhibits an ABCG2 confor-
mation-dependent accessibility.[9] Treatment with the
ABCG2 inhibitor Ko143 or ATP depletion can stabilize
215ABCG2 in a specific conformation that increases 5D3 bind-
ing and results in an improved immunofluorescence signal.
[10] Figure 1 shows the effect of Ko143 on 5D3 binding of
ABCG2 on HUES3 hESCs detected by flow cytometry. In
the case of endogenous expression levels, applying ‘tricks’ like
220these can make the difference between detectable and non-
detectable presence of transporters in intact cells. It is impor-
tant to emphasize, however, that the 5D3 antibody is only
one among the antibodies featuring conformation-dependent
binding characteristics, as similar conformation-dependent
225binding was reported in the case of the ABCB1-detecting
antibodies, MRK16 [19] and UIC2 [20]).
An important question is the localization of the transporter
proteins. In many cases, drug transporters can perform their
original function only when localized to the cell surface,
230while during their production or membrane reshuffling,
they temporarily reside in intracellular membrane compart-
ments. Since several monoclonal antibodies react with intra-
cellular epitopes of the transporter proteins, for
immunodetection, the cells have to be permeabilized, and a
235proper distinction between plasma membrane (PM) or intra-
cellular membrane localization of a given transporter is not
an easy task. In fact, PM and intracellular membrane trans-
porter expression profiles can only be distinguished when
specific organelle (membrane) markers are co-stained with
240the transporters, and microscopy-based applications are
used for detection. When antibodies recognizing cell surface
epitopes are available, these allow the investigation of intact
cells and offer an easy way for the quantitative assessment of
cell surface localization,  for example by flow cytometry.
245Figure 2 shows ABCG2 staining in intact HUES3 embryonic
stem cells with the 5D3 antibody, recognizing cell surface
epitope and, in parallel, the BXP-21 and BXP-34 antibodies,
recognizing intracellular epitopes as well in fixed HUES3
cells. A similar labelling feature obtained by these antibodies
250suggests that in HUES3 cells, the expression of ABCG2
might be restricted to the PM . However, the absence of
intracellular localization should be investigated by micro-
scopy-based detection techniques as well.
2.3. Studying transporter functionality
255While most of the transporter substrates are either toxic to or
metabolized by the transporter expressing cells, relatively
The importance of drug transporters in human pluripotent stem cellsAQ1
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inert fluorescent dyes are most suitable for directly assessing
drug-related transporter activity. By now, cellular or vesicular
uptake and related fluorescence measurements are widely
260 applied, and for the three major ABC multidrug transporters
(ABCG2, ABCB1  and ABCC1), several fluorescent
substrates have been described and successfully used in the
literature.[21,22] Some of the indicator dyes (e.g. rhodamine
123, 3,39-diethyloxacarbocyanine iodide (DiOC2(3)), cal-
265cein-AM, chloromethylfluorescein diacetate (CMFDA),
Pheophorbide A) are transported by one or two of the three
Figure 1. Indirect staining of ABCG2 with 5D3 monoclonal antibody, with or without the addition of ABCG2 inhibitor Ko143
in intact HUES3 hES cells. GAM-PE was used as secondary antibody. IK: isotype control.
Figure 2. Indirect staining of ABCG2 with 5D3 monoclonal antibody (+Ko143) in intact hESC cells, as compared to Bxp21 and
Bxp34 antibody staining in fixed HUES3 hES cells. GAM-PE was used as secondary antibody, and corresponding IgG primary
antibodies were used as isotype control.
Apáti et al.
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transporters, while mitoxantrone is a substrate of all three
proteins.[21,22] However, point mutations can alter sub-
strate specificity as it was shown for doxorubicin and rhoda-
270 mine 123 in the case of ABCG2.[23,24] Recently, novel
fluorescent probes (Green and Gold eFluxx-IDH® MDR
probes), which are substrates of ABCB1, ABCG2 and
ABCC1 transporters, have been suggested to assess low-level
transporter expression and function.[25] For measuring SLC
275 transporter activity, an array of fluorescent substrate mole-
cules has also been developed (see [22]). The fluorescent
compounds used for the uptake measurements may be sub-
strates for more than one transporter, and the effect seen
might be the result of synergistic transport mechanisms.
280 Therefore, the use of selective inhibitors is highly recom-
mended, while application of weak or non specific inhibitors
(e.g. verapamil for ABCG2) should be avoided.[26,27]
The first functional identification of tissue-derived cells
with stem cell-like properties was achieved by a lower level
285 accumulation of the Hoechst 33 342 dye in such cells, form-
ing a ‘side population’.[28,29] It has been documented that
the active extrusion of this dye by the ABCG2 protein is
responsible for this phenotype,[30] while other ABC trans-
porters may also be relevant in Hoechst 33 342 extrusion.
290 For assessing functionality of ABC-MDR transporters, the
frequently used fluorescent dyes (CalceinAM, mitoxantrone,
Hoechst, or DCV) provide a strong fluorescent signal, and
uptake assays can be carried out by flow cytometry or micro-
scopy-based techniques (e.g. fluorescence and confocal
295microscopy or high content screening) when assessing cells
with high-level transporter expression. Mostly two samples
are compared during the investigation: one contains cells
incubated with a transporter-specific inhibitor and the fluor-
escent substrate, while the second sample is only incubated
300with the fluorescent dye. The fluorescence signal in the two
samples is detected as an end point assay or by following
time-course of the uptake, and functionality is determined
based on the difference of the two signals.
In cases when drug transporters are present only in low
305levels, only kinetic measurements of the dye uptake are
appropriate to assess functionality.[7] End point measure-
ments (as applied by Zeng and colleagues [6]) may fail to
provide appropriate information about functionality and
expression, since low levels of endogenously expressed trans-
310porters will not be able to prevent dye accumulation in the
presence of a huge amount of dye in excess for extended
periods of time. Therefore, end point measurements may
show much lower transporter levels than immunolabelling
or kinetic studies (see [7,13,31,32]).
315Kinetic dye transport measurements can be carried out by
flow cytometry, as ‘continuous flow’ measurements.[33,34] 
Figure 3 shows a mitoxantrone uptake measurement in
HUES9 hES cells (upper panel) and the effect of the
Figure 3. Kinetic transport measurement of mitoxantrone (100 nM) with or without inhibition of ABCG2 by Ko143 (5 µM) in
HUES9 hESC cells. Each tick of the time parameter represents 10 ms, the duration of the measurement was 3 min.
The importance of drug transporters in human pluripotent stem cells
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Ko143 ABCG2 inhibitor (lower panel). A clear shift in the
320 mitoxantrone signal is detectable in the presence of Ko143 as
compared to mitoxantrone treatment alone, indicating that
this method allows the assessment of functionality even when
transporters are expressed at low levels. An important issue is
to reduce the excess dye to the lowest possible level to render
325 the transport process detectable; in our experience, the use of
100 nM of mitoxantrone allows the detection of the signal by
flow cytometry. However, a high number of cells is needed
for this type of measurement, which significantly hampers
the feasibility of this method in the case of hPSCs.
330 In pluripotent stem cells, transporter expression may be
heterogeneous. As shown by us [7] and others,[8] heteroge-
neity in hESC cultures regarding ABCG2 expression is man-
ifested in a way that some colonies express ABCG2, while
others do not, although the amount of colonies staining
335 positive for ABCG2 shows high variability (see below in
 Section 3). Therefore, to achieve the highest possible sensi-
tivity, the kinetics of the fluorescent dye uptake has to be
selectively analysed in ABCG2-positive and -negative cells
(colonies). This can be done by confocal laser scanning
340 microscopy measurements, where differences in Hoechst
dye uptake kinetics of ABCG2-positive and -negative cells
can be investigated simultaneously. The inhibition of the dye
uptake by selective inhibitors should also be employed to
accurately identify the transporter involved in dye extrusion.
345 For example, when treated with the selective ABCG2 inhi-
bitor Ko143, an increased dye uptake can be observed in
ABCG2-positive hPSCs, while the time course of the dye
uptake in ABCG2 negative cells is not affected appreciably by
the inhibition of the transporter.[7] It has to be mentioned
350 that the specificity of Ko143 for ABCG2 is concentration
dependent, since Ko143 at higher concentrations has an
effect on both ABCB1 and ABCC1 transport activity.[35,36]
In addition to direct transport measurements, the ability of
the endogenously expressed transporters to protect the cell
355 population from effects of drugs and xenobiotics in long-
term studies should also be examined. In these experiments,
the goal is to find the range of drug concentrations at which
the transporter-expressing pluripotent cells can survive, while
the inhibition of the transporter results in the eradication of
360 this cell population. This concentration can be quantitated
by viability assays designed for high-throughput fluorescence
or absorbance measurements.[37] In addition, the examina-
tion of pluripotency markers during these types of experi-
ments also have to be performed, since some hPS cells may
365 survive the drug treatment or toxic stress, but respond with
rapid cell differentiation.[31]
3. Expression of ABC transporters in human
embryonic stem cells and in early differentiation
ABC membrane proteins play a major role in pharmacoki-
370 netic variability of many drugs; therefore, they are intensively
investigated in human tissues and tumours.[38] Moreover,
the expression profiles of ABC transporters could be also
important in performing stem cell-based cell therapies. Still,
until now, there are only three detailed studies published
375about ABC transporter expression in pluripotent stem cells.
All these studies used TLDA for the determination of mRNA
levels of the ABC proteins.
Tang et al. [39] analysed a large amount of data by
comparing 11 hematopoietic stem cells (HSCs) with six
380unrestricted somatic stem cells, seven mesenchymal stem
cells, three multipotent adult progenitor cells, and three
ESC lines (namely HUES1, HES2, and HES3). All the
somatic stem cell samples originated from different donors,
such as the embryonic stem cells. The authors found that
385each type of stem cells showed a unique ABC transporter
profile while these profiles clustered together. Non-HSCs
exhibited rather similar ABC transporter expression profiles,
suggesting that in ABC transporter expression, the tissue
specificity is a more important determinant than the genetic
390background. In all stem cells, the mRNA for ABCA1,
ABCB6, ABCB8 and ABCD3 were found to be appreciably
expressed. Regarding hESCs, the expression of ABCA3,
ABCA7, ABCC8 and ABCG2 mRNAs were significantly
higher, while ABCA8 and ABCC9 mRNAs were much
395lower (about 1000-fold lower) than in the non-HSC types.
As a summary, this study provided a great deal of informa-
tion about the expression of ABC transporters in various
types of stem cells and highlighted the importance of tissue
specificity.
400The work from Barbet et al. [40] presented the ABC
protein mRNA expression profiles of three hESC lines (H7,
hES2 and hES3), two hESC-derived MSCs and six patient-
derived MSCs, by using TLDAs. They found that most of
the ABC proteins (44 from 48) were expressed in hESCs,
405although some of them showed significant but low-level gene
expression. Their data confirmed that hESC-derived MSCs
represent an intermediate state between hESCs and patient-
derived MSCs, according to ABC protein expression. They
also found mRNA of ABCE1, ABCF1-3, ABCB6,7,8,10,
410ABCC1,10 and ABCD3 appreciably expressed in all cell
types, similarly to that shown by Tang et al. This analysis
demonstrated that the mRNA of PM transporters showed the
most variable expression levels among the ABC proteins.
Based on this finding, they suggested an important role of
415ABC membrane transporters in pluripotency, and this work
demonstrated that the ABC protein mRNA expression pro-
file can serve as a tool for identification of the developmental
state of the samples.
Erdei et al. [13] used an isogenic system to characterize the
420differentiation status of stem cells, based on ABC protein
mRNA expression levels. HUES9 hES cells and their deriva-
tives (cardiac, neural and mesenchymal cells) were investi-
gated. After the detailed characterization of pluripotency and
differentiation status of the hESC-derived cell types (using
425TLDA for Human Stem Cell Pluripotency), they studied the
Apáti et al.
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mRNA expression of ABC transporters by TLDA for ABC
transporter genes. The results showed a strong correlation
between ABC protein expression and the developmental
status of the samples, that is the more differentiated tissues
430 clustered distinctly from those of the hESC samples. ABCE1,
ABCF1-3, ABCB6,7,8,10, ABCC1,4,5 and ABCD3,4
mRNAs were appreciably expressed in all samples, similarly
to that found in the work of Barbet et al. This paper also
showed that ABCG2 mRNA expressed at a significantly
435 higher level in hESCs than in the differentiated derivatives.
For validation of mRNA data, the expression of the most
significant ABC transporter proteins (ABCA1, ABCB1,
ABCB6, ABCC1, ABCC6 and ABCG2) was also directly
analysed by FACS and confocal microscopy, by using reliable
440 specific antibodies. The protein expression showed a close
correlation to the mRNA data.
An important issue is the potential expression of the
ABCG2 multidrug transporter in stem cells. ABCG2 expres-
sion and the related side-population characteristics were
445 shown earlier as a marker for tissue-derived stem cells,[4,5] 
and in earlier studies, this expression was also used as a marker
of ‘stemness’ in pluripotent stem cells.[41–43] The mRNA
expression of ABCG2 was demonstrated by RT-PCR in
human embryonic cell lines H1,[42] BG01 and BG02,[43] 
450 and GE01, GE09, BG01, BG02, and TE06,[41] while the
protein expression was demonstrated only in mouse cell lines.
[41] As a next step, our group confirmed the mRNA expres-
sion by qRT-PCR and showed the ABCG2 protein expression
by using 5D3 antibody in flow cytometry and confocal micro-
455 scopy in the human pluripotent embryonic stem cell lines,
HUES1, HUES3, HUES4 and HUES9.[7,13,32] The
ABCG2 transporter showed PM localization and heteroge-
neous distribution on population level in all studied cell
lines. Moreover, the function of ABCG2 was demonstrated
460 by a kinetic microscopy measurement of Hoechst dye uptake
in undifferentiated HUES9 cells. This uptake, reduced by
ABCG2 protein function, was modulated (the dye uptake
increased) by a specific ABCG2 protein inhibitor.[7]
Following these observations, controversial findings were
465 published by Zeng et al., showing no expression of ABCG2
in several pluripotent cell lines, including the embryonic stem
cells H9, HUES1 and CT2 and two human iPS cell lines,
iPS(IMR90)-1 and iPS(foreskin)-1.[6] The investigation of
the mRNA levels by RT-PCR and studying ABCG2 protein
470 expression by monoclonal antibody staining and Hoechst dye
uptake did not show the sign of ABCG2 expression.
Meanwhile, the differentiated stem cell derivatives towards
trophoblasts showed all the signs of ABCG2 expression.
In contrast, the experiments by Padmanabhan and collea-
475 gues confirmed the ABCG2 mRNA expression in 9 hESC
lines (BG01, BG02, BG03, ES02, SA01, TE03, UC01,
UC06, WA01 and WA09), while they found no ABCG2
protein expression by Western blot analysis. When WA01
and WA09 cells were differentiated towards trophoblast
480 direction by adding BMP4 to the culture media, an elevated
ABCG2 expression was observed both at the mRNA and
protein levels, while BG03 cells showed no sign of ABCG2
expression after BMP4 treatment.[8]
A further study by Hirata et al.[14] showed well measurable
485ABCG2 expression at the mRNA level in the hESC lines
KhESC-1, KhESC-2, KhESC-3, KhESC-4 and KhESC-5, as
well as in three hiPSC lines (201B7, IMR90-1 and IMR90-4).
These authors also found appreciable ABCC1 mRNA expres-
sion in the undifferentiated cells, while detected no expression
490for ABCB1 and ABCC2. When the pluripotent cells were
treated by retinoic acid, together with the appearance of the
CDX2, a differentiation marker for placenta, ABCG2 and
ABCB1 expressions also significantly increased.
In Table 1, we summarized the results obtained in the
495literature regarding ABCG2 expression. The inconsistent
results might come from different genetic background of
the cell lines studied, a lack of sensitivity of the detection
methods (see Section 2.1 above), different forms of cellular
states or stress conditions, suboptimal growth conditions and
500different handling of the hESC cultures in vitro. These may
include the different growth media with various growth
factors, extracellular matrices, passaging methods, and so on.
As suggested by Padmanabhan et al. [45], the observed
differences in ABCG2 expression may also result from the
505variable regulation of ABCG2 at  all the levels, including
transcriptional, post-transcriptional, translational and/or
post-translational levels. In addition, developmental changes
significantly alter the stem cell ABC protein expression pro-
files [13,39,40]; thus for any transporter studies, it is crucial
510to exactly determine the differentiation status of the cell
population examined.
The results for ABCG2 expression are more consistent
when relatively pure hPSC-derived, partially differentiated
cell types were analysed. MSCs differentiated from hESCs
515did not express ABCG2 either at mRNA [13,40] or at the
protein level.[7,13] Similar results were found examining
ABCG2 expression in ES-derived cardiomyocytes.[13,14] 
Differentiation towards trophoblasts showed an opposite
effect on ABCG2 mRNA and protein expression. Stem cell
520differentiation into trophoblast direction, induced by BMP4
[8,43] or retinoic acid,[14] significantly increased ABCG2
expression. On the other hand, controversial results were
obtained when ABCG2 mRNA expression was investigated
in various spontaneous stem cell differentiation models.
525[6,7,13,14] This variability may be the result of the emer-
gence of various differentiated subpopulations with different
ABCG2 expressions during such a process.
Despite  some contradictory results regarding ABCG2
expression levels and distribution in undifferentiated pluri-
530potent stem cells, there are convincing studies about the
important role of this multidrug transporter in the defence
of pluripotent cells against harmful effects. When studying
the effect of hypoxia/reoxigenation in BG01 and H9 plur-
ipotent ES cell lines, Das and colleagues [44] found the
535emergence of an ABCG2+/SSEA3+ population which
The importance of drug transporters in human pluripotent stem cells
Expert Opin. Drug Metab. Toxicol. (2015) 00(00) 7
showed ‘enhanced stemness’ phenotype, that is decreased p53
expression and elevated HIF-2alpha, OCT4 and NANOG
expression, and enhanced cytoprotective features both in
vitro and in vivo. As demonstrated by Erdei et al. [31] in
540 HUES9 embryonic stem cells, the functional presence of
ABCG2 provides important protection against various harm-
ful conditions, including physical stress, drugs and UV light
exposure. The stress-induced production of metabolites could
induce genetic and/or epigenetic changes (such as DNA
545methylation) which could potentially remove the cells from
the carefully balanced state of pluripotency and induce dif-
ferentiation. ABCG2 could potentially remove such stress-
induced metabolic compounds, thus protecting the stem
cells. Although only a few systematic studies have been
550published on this topic, they point towards an important
protective role of ABCG2 in various stem cells, potentially
operating not only at the cellular but also at the population
level.[31,44]
Table 1. Summary of the results obtained in the literature regarding ABCG2 expression.
Cell line Array RT-PCR IC FACS WB Hst Refs
iPS 201B7 (MEF) Yes Hirata [14]
BG01 (MEF) Yes * No No Padmanabhan [8]
BG01 (MEF) Yes Das [44]
BG01 (MEF) Yes Zeng X [43]
BG01 (MEF) Yes Bhattacharya [41]
BG02 (MEF) Yes * Padmanabhan [8]
BG02 (MEF) Yes Zeng X [43]
BG02 (MEF) Yes Bhattacharya [41]
BG03 (MEF) Yes * No Padmanabhan [8]
CT2 (MG) No No No No Zeng H [6]
E0S2 (MEF) Yes Barbet [40]
ES02 Yes Tang [39]
ES02 (MEF) Yes * Padmanabhan [8]
ES03 Yes Tang [39]
ES03 (MEF) Yes Barbet [40]
GE01 (MEF) Yes Bhattacharya [41]
GE09 (MEF) Yes Bhattacharya [41]
HUES1 Yes Tang [39]
HUES1 (MEF) Yes * Yes Yes Yes Apáti [7]
HUES1 (MG) No No No No Zeng H [6]
HUES3 (MEF) Yes * Yes Yes Erdei [13]
HUES4 (MEF) Yes * Yes Yes Erdei [13]
HUES4 (MEF) Yes * Yes Yes Sarkadi [32]
HUES9 (MEF) Yes Yes Yes Erdei [13]
HUES9 (MEF) Yes * Yes Yes Apáti [7]
iPS IMR90-1 (MEF) Yes Hirata [14]
iPS IMR90-1 (MG) No No No No Zeng H [6]
iPS IMR90-4 (MEF) Yes Hirata [14]
iPS(FS)-1 (MG) No No No No Zeng H [6]
KhESC-1 (MEF) Yes Hirata [14]
KhESC-2 (MEF) Yes Hirata [14]
KhESC-3 (MEF) Yes Hirata [14]
KhESC-4 (MEF) Yes Hirata [14]
KhESC-5 (MEF) Yes Hirata [14]
SA01 (MEF) Yes * Padmanabhan [8]
TE03 (MEF) Yes * Yes Padmanabhan [8]
TE06 (MEF) Yes Yes Bhattacharya [41]
UC01 (MEF) Yes * Padmanabhan [8]
UC06 (MEF) Yes * Padmanabhan [8]
WA01 (MEF) Yes Ginis [42]
WA01 (MEF) Yes * No No Padmanabhan [8]
WA07 (MEF) Yes Barbet [40]
WA09 (MEF) Yes Das [44]
WA09 (MEF) Yes * No Padmanabhan [8]
WA09 (MG) No No No No Zeng H [6]
Cell lines are listed according to their NIH codes. The abbreviations of the techniques are array: TaqMan® ABC gene Arrays (TLDAs) ; IC:  immunocytochemistry; Hst:
Hoechst dye uptake measurements; and WB:  Western blot.  ‘*’ stand for quantitative RT-PCR. ‘Yes’ indicates when ABCG2 expression was found, ‘no’ indicates when
ABCG2 expression was under the detection level and empty spaces were used when data are not available.
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4. Solute carrier (SLC) transporters in human
555 embryonic stem cells and in tissue differentiation
SLCs are solute transporting integral membrane proteins,
named and grouped based on functional criteria, while sequence
homology between the members of this large superfamily (com-
prising of almost 400 different transporters grouped into 52
560 families) is small or non existing.[46–51] Most SLC proteins
contain large transmembrane domains with typically 10–12
alpha helices and catalyse the transmembrane movement of
diverse molecules, ranging from large organic anions to organic
cations, ions and gases. Many forms of transport, from unidir-
565 ectional movement to obligatory co-transport or coupled
exchange, are catalysed by the various SLC proteins. Within
the 52 families, based on structural, evolutionary, functional
and sometimes historical basis, the proteins are named as SLC +
family number + letter of subfamily + number of isoform (e.g.
570 SLC2A1, a glucose exchange transporter).
In many cases, SLC transporters are localized to the PM ,
and their function is to promote the uptake of cellular nutri-
ents, endobiotics and signalling molecules; therefore, they are
often denoted as ‘uptake transporters ’. Still, the function of
575 numerous SLCs also involves the removal of toxic endo- and
xenobiotics, the regulation of pH or to move molecules
between intracellular compartments (see [46,50]).
Currently, we have little information regarding the role of
SLC transporters in pluripotent stem cells and a little more
580 in early cell differentiation. In the huge comprehensive
review collection, detailing the structure, function and
disease-connections of all groups of SLC transporters in
2013 (see [52]), there is hardly any mentioning of stem cell
connections, and in the following years, this information has
585 also been very limited. Since SLC transporters can serve both
as drug targets and mechanisms to facilitate or reduce drug
delivery to stem cells and differentiating tissues, the explora-
tion of their role in these cell types should be of utmost
importance.
590 Specific nutrient transporters, for example the isoforms of
the SLC2 (PM, sugar, mostly glucose) and SLC3 (PM,
mostly amino acid) transporters, serve as markers during
stem cell differentiation, since differentiated tissues show
major changes in their expression levels and patterns. As
595 examples, in the fertilized egg, undifferentiated stem cells or
preimplantation embryos, the major glucose transporter is
SLC2A1 (GLUT1), while in many differentiated tissues
SLC2A2, A3 or A4 take over this role. In induced and
directed hepatocyte, enterocyte or blood–brain epithelial
600 cell differentiation from embryonic stem cells, in addition
to ABC transporters (see above), several SLC-type transpor-
ters are important developmental indicators. [1,15,53–60] 
During stem cell differentiation into early kidney tissues,
the expression patterns of the SLC12A1 (NA/K/Cl – thick
605 ascending limb the of Henle’s loop), A3 (Na/Cl – distal
convoluted tubule) and the SLC34A1 (Na/phosphate, prox-
imal tubule) transporter proteins can be efficiently used as
markers for kidney tubule development. [61] Similarly, spe-
cific substrate transporters in the SLC1 (PM glutamate,
610aspartate or other neurotransmitter carriers), in the SLC6
(PM neurotransmitter and amino acid transporters) and in
the SLC17 family (vesicular glutamate transporters) are
recognized as regulated marker proteins, especially in neuro-
nal differentiation.[62] An isoform of the PM Na-H exchan-
615ger (SLC9) proteins, SLC9C1, is selectively expressed in
spermatozoa; SLC11A2 (a metal transporter) and SLC19A2
(a thiamin transporter) are essential in erythroid progenitor
cells, while SLC16A13 (a PM proton-linked monocarboxy-
late transporter) is almost exclusively localized in bone mar-
620row stem cells (see [63,64], and [52,65]).
The SLC transporters having important role in drug and
xenobiotic transport include the family of SLCO (formerly
SLC21) PM organic anion transporters, the SLC22 PM
zwitterion and organic cation and anion transporters, and
625the SLC47 (MATE, Multidrug and Toxin Extrusion) a
family of PM drug transporters. In the following section,
we review the potential role of these proteins in stem cells
and early differentiation.
The human SLCO (formerly SLC21) family of Organic
630Anion Transporting Polypeptides (OATPs) comprises of 11
PM transmembrane proteins, with variable transport
mechanisms. Many SLCO transporters are preferentially
expressed in the liver, kidney and the blood–brain barrier 
and are involved in the transport of amphipathic, anionic and
635even cationic compounds of endogenous (e.g. steroids, pros-
taglandins, bile acid etc.), or exogenous (e.g. cholesterol low-
ering statins, antibiotics and anticancer drugs) origin. OATPs
may influence the pharmacokinetics of several clinically rele-
vant drugs and evoke complex drug–drug interactions.[66]
640The pattern of OATP expression (particularly SLCO1B1
and 1B3) has been already used to follow early hepatic,
intestinal and blood–brain barrier epithelial cell differentia-
tion from pluripotent stem cells.[15,67] While in foetal
tissues, the OATP levels are low, fully differentiated hepato-
645cytes have high expression levels for selected OATPs, thus
report the success of end-stage hepatocyte differentiation.[57] 
OATPs have also been used to characterize potential cancer
stem cells.[68–70] Since the uptake of various anticancer
drugs (e.g. methotrexate, taxol, flavopiridol or imatinib) is
650mediated by OATPs, their increased expression in some
cancer tissues, as compared to normal cells, may help to
devise suitable tumour therapies.[71]
The 13 members of the SLC22 family are PM transporters
for organic cations (OCTs), organic cations and zwitterions
655(OCTNs) and, in the case of some members, organic anions
(OATs). These proteins contain 12 transmembrane helices,
catalyse facilitated diffusion (OCTs, OCTNs), anion
exchange (OATs), or Na+/zwitterion co-transport (OCTNs).
SLC22 proteins are major players in intestinal absorption and
660hepatic and renal excretion of drugs, xeno- and endobiotics
(including neurotransmitters, e.g. acetylcholine, cAMP,
cGMP or prostaglandins), and are also functionally expressed
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in neuronal and cardiac tissues. SLC22A1-3 (OCTs) are
involved in the uptake of numerous therapeutic agents, includ-
665 ing metformin, antiviral drugs or irinotecan, as well as in
cisplatin toxicity in cancer, while SLC22A12 (URAT1) is a
major uric acid transporter in humans.[72]
There are again very few data for the function of the
SLC22 type transporters in stem cells – these proteins are
670 significantly expressed only during tissue differentiation.
Interestingly, in murine embryonic stem cells, the inhibition
of acetylcholine release through organic cation transporters
significantly affects cellular homeostasis, indicating that non-
neuronal acetylcholine and its release through OCTs may
675 have a functional role in embryonic stem cells.[73] SLC22A4
(OCTN1) is widely expressed in numerous tissues and rela-
tively highly expressed in mesenchymal stem cells and neu-
ronal progenitor cells (NPCs). This protein was found to be a
transporter for ergothioneine (ERGO), a zwitterionic natural
680 antioxidant, which seems to have an important physiological
role in NPCs.[74] OCTN1-mediated uptake of ERGO in
NPCs inhibits cellular proliferation, while promotes neuronal
differentiation by modulating the expression of basic helix–
loop–helix transcription factors.[75]
685 Hormones and transcription factors in the process of tissue
differentiation from embryonic stem cells significantly mod-
ulate the expression of SLC22A1 (OCT1), SLC22A2
(OCT2), SLC22A6 (OAT1) and SLC22A8 (OAT3).
Although with practically unknown function, SLC22A18 is
690 expressed at relatively high levels in adult and foetal kidney
and liver and in differentiated kidney proximal tubules.
Mutations of the SLC22A18 gene cause rhabdomyosarcoma 
and are associated with lung cancer.[72]
Interestingly, SLC22A2 (OCT2), SLC22A3 (OCT3) and
695 SLC22A18 are among the not too many (in this case mater-
nally) imprinted genes in the hESCs, and the expression
levels of these proteins are greatly increased during EB for-
mation and further tissue differentiation.[76] This strong
developmental regulation also alters their imprinting status,
700 resulting in variable monoallelic and biallelic expression pat-
terns in a lineage-specific manner,[77] which may be impor-
tant in developmental physiology or disease development.
The SLC47A1 and A2 (MATE1 and 2) proteins are PM 
efflux transporters mediating the H+-dependent excretion of
705 organic cations in various epithelial tissues. MATEs are multi-
specific transporters and export a number of endogenous
organic cations as well as drugs, including cimetidine, metfor-
min, guanidine, procainamide, cephalexin or cephradine. The
driving force for organic cation extrusion byMATEs is provided
710 by the oppositely directed proton gradient. In humans,MATE1
is highly expressed in the kidney and liver, MATE 2 preferen-
tially in the kidney, and both proteins are localized at the apical
membrane of proximal tubules and hepatocytes.[78,79] 
Human MATE1 is also detectable in other tissues, including
715 adrenal gland, skeletal muscle, testis and the placenta.
A relatively more detailed information is now available
for the presence and role of SLC transporters in the
feto–maternal complex tissue of the human placenta.
Between the first and third trimester, there are major altera-
720tions in the trophoblast SLC expression patterns: SLC2A3/
GLUT3, SLC22A3/OCT3, SLC38A5 and SLCO4A1/
OATP4A1 are highly expressed in the first trimester and
decrease during gestation, while the expression of
SLCO2B1 shows an opposite pattern.[80] The syncytiotro-
725phoblasts and the cytotrophoblast also show different expres-
sion patterns for several transporters. MATE1 is expressed at
the maternal side of the trophoblast cells in the placenta in
the first trimester, while its expression becomes negligible in
the term placenta, thus this transporter may have a protec-
730tive, toxin elimination function for the foetus in early gesta-
tion stages.[67] Interestingly, some of the SLC transporters,
which play a key role in the neurotransmitter transport and
the pharmacological treatment of anxiety and depression,
may have an important role in drug abuse during preg-
735nancy.[81] Cocaine and amphetamine by inhibiting the pla-
cental SLC transporters cause harmful effects, such as
premature delivery or growth retardation, by elevating sero-
tonine and norepinephrin concentrations in the intervillous
space. Also, a decreased expression of SLC22A3/OCT3 may
740be involved in preeclampsia.[82]
5. Regulation of ABC transporter expression –
focus on ABCG2
Our knowledge on gene expression regulation at the RNA
level are constantly becoming far more complex than pre-
745viously appreciated, due to the unprecedented speed of data
generated by the next generation sequencing (NGS) meth-
odologies,[83] and projects aiming to decipher potential
functions of the non-protein coding regions of the genomes,
such as the ENCODE project.[84,85] By now, the complex
750regulatory network of transcriptional and splicing regulation
is joined by the equally complex network of non-coding
RNAs and post-transcriptional regulatory players, most pro-
minently the microRNAs (miRNAs).[86] To various levels
and contributions, these regulatory processes seem to operate
755on the expression of every gene, and drug transporters are no
exception from these. The translational and post-translational
regulation of membrane transporters are very complex, and
this might have been the reason why the RNA regulation of
the corresponding genes gained much less attention until
760recently. Nevertheless, more and more data point out that
in certain cell types, such as in various stem cells, the fine-
tuning of transporter regulation at the RNA level plays a
crucial role in transporter function, often having medical
relevance, as in the case of multidrug transporters.
765There are numerous studies describing the transcriptional
regulation of drug transporters in various cell lines, although
very few data are available about these mechanisms in
stem cells. Since extensive reviews are available on these
topics,[21,87] the detailed description of this regulation is
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770 beyond the scope of the present review. In the following
sections, we highlight some aspects of mRNA regulation of
transporters, especially the importance of the noncoding,
 UTRs in membrane protein expression that must be inte-
grated into the complex picture of transporter regulation.
775 5.1.  Alternating the 5
0
 UTR – regulation by transcription
and splicing
50 UTRs can regulate the translation efficiency from the mRNA
by various mechanisms: by upstream open reading frames, they
can interfere with the translation from the canonical start
codon; by upstream alternative translation start sites (AUGs,
780 GUGs, etc.), they may produce longer protein isoforms; or
alternatively, 50 UTR binding factors can regulate the stability
of the transcript itself, resulting in lower amount of the corre-
sponding protein.[88] In addition, one gene might produce
more alternative 50 UTR sequences, either by distinct transcrip-
785 tional start sites or alternative splicing, with the potential of
distinct regulation of the different mRNAmolecules and, there-
fore, of the encoded protein species. A prominent example is the
ABCG2 multidrug transporter, where at least 3 different non-
coding leader exons exist (both in human and in mouse cells),
790 producing different 50 UTR containing mRNAs but encoding
for the same protein species.[89,90] 
Apart from having medical relevance in cancer therapy,
this gene is expressed in embryonic stem cells[7,91] and was
proven to be the molecular basis for the so-called  side
795 population phenotype.[30] An intriguing observation is that
only two of the 50 UTR variants (having exon 1a and 1b) are
expressed in human embryonic stem cells, whereas the third
variant (with exon 1c) is only present in dendritic cells of
hematopoietic origin.[7] The ABCG2 5
0
 UTR pattern is dif-
800 ferent in various cell types, but certain drug-selected cell lines
also express the 1a and 1b variants similarly to stem cells.
[7,90] The need of high ABCG2 protein levels in those cell
types could be achieved by the usage of alternative transcrip-
tional start sites: certain signal transduction pathways seem to
805 distinctly regulate the exon 1a and exon 1b containing tran-
scripts.[92] Nevertheless, the role in translation regulation of
the different 50 UTRs could also be important, and the pre-
sence of certain variants might represent selective advantage
for the cells by more efficient translation of this multidrug
810 transporter (Sándor S et al., manuscript in prep.)
Until now there have been relatively few studies on transpor-
ter mRNA 50 UTR regulation in stem cells, but some key
examples for membrane proteins highlight the importance of
investigating this level of regulation. The mouse and the human
815 folate receptor-alpha membrane proteins have been shown to be
upregulated during retinoic acid-induced differentiation of
embryonic stem cells, producing a distinct pattern of various
50 UTR containing transcripts.[93] The exact functional differ-
ences of the mRNA variants remain to be elucidated but the
820 evolutionary conservation indicates their significance. A more
detailed characterization of the human PTCH1b
transmembrane protein expression pattern revealed a complex
regulation via alternative 50 UTRs: upstream open reading
frames motifs, upstream AUG codon producing an
825N-terminally longer protein and internal ribosomal entry site
(IRES)-like sequences as cis-regulatory elements can increase the
membrane protein repertoire, especially under certain stressful
conditions, including hypoxia.[94] In addition, polymorphisms
in 50 UTR sequences might also be associated with complex
830phenotypes, such as birth weight in the case of solute carrier
family 44 variants.[95] The mechanisms by which the functions
of different 50 UTRs are manifested are often not clear as yet,
and this indicates the need of further studies aiming to specifi-
cally investigate these regulatory levels for membrane
835transporters.
5.2.  Regulation by the 3
0
 UTR – the miRNA network
The regulatory role of the 30 UTRs are also well known:
length and sequence of this region influence mRNA stability,
translation efficiency and often mRNA localization inside the
840cell.[96] In recent years, it became evident that at least half of
the human protein-coding genes have variable 30 UTR con-
taining mRNAs, produced by alternative cleavage and poly-
adenylation.[97] A striking observation was that this
phenomenon strongly influences membrane protein expres-
845sion and localization: when studying the role of alternative
30 UTRs, Berkovits and Mayr found that a long 3
0
 UTR
sequence increases the efficiency of cell surface expression of
CD47 membrane protein.[98] It turned out that the
sequence exerts its function by recruiting the HuR and
850SET proteins to the site of translation, and their interaction
with the freshly translated cytoplasmic domain of CD47
results in the translocation of CD47 to the PM . This traf-
ficking of different 30 UTR mRNA variants by the HuR
protein also affects the cell surface expression of other mem-
855brane proteins, and it could be a widespread mechanism by
which transporter protein localization and function could be
regulated without changing the coding region of the gene.
Since the HuR protein have been shown to bind numerous
mRNAs,[99] this regulatory mechanism could influence
860other important drug transporters, potentially involved in
early differentiation processes from stem cells.
A prominent pathway by which the role of 30 UTRs is
manifested is the miRNA regulatory pathway. miRNAs are
small, non-coding species binding to these sequences, and
865initiating the translational repression and/or the decay of the
target mRNAs.[86] One miRNA could target several mRNA
species and vice versa, one particular mRNA 30 UTR gener-
ally contains several different miRNA binding sites. By this
complex regulatory network, the exerted effects of miRNAs
870are comparable to that of transcription factors, playing
important roles in all aspects of cellular physiology. As
such, drug transporters are also under the influence of
miRNA regulation. The ABCG2 multidrug transporter,
being expressed in human embryonic stem cells (see above,
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875 part 5.1), has also different 30 UTR variants produced by
alternative mRNA cleavage and polyadenylation. We could
show earlier that only the shorter version is detected in
undifferentiated human embryonic stem cells, which can
therefore escape the regulation of several miRNAs, the bind-
880 ing sites of which are missing from this shorter 30 UTR.[7] 
The physiological significance of this regulation was provided
by independent studies: drug resistant cancer cell lines
express shorter 30 UTRs of ABCG2 mRNA, which enables
them to escape the negative regulation by certain miRNAs,
885 including hsa-miR-328 and hsa-miR-519c.[100,101] In
addition, this phenomenon should be considered when new
alternative ABC transporter or membrane protein inhibitors
are being developed, as the miRNA-based novel products
may not work efficiently for different tumours.[102,103] 
890 These examples underline the need of studies aiming to
decipher the role of miRNA regulation in drug transporter
expression; apart from understanding cellular mechanisms of
these subtle mRNA regulations, these molecular details
would definitely have medical importance in the future.
895 6. Conclusion
Drug transporters play an important role in protecting human
pluripotent stem cells and their differentiated progenies
against toxic materials. These large transmembrane proteins
catalyse the movement of a wide variety of chemicals, includ-
900 ing drugs as well as xeno- and endobiotics through cellular
membranes. The major human drug transporter groups
include the ABC transporters, working as ATP-fuelled drug
‘exporters’ and the SLC transporters, with various substrate
transport directions and mechanisms. Both ABC and SLC
905 drug transporters may serve as markers for a certain stages of
stem cell differentiation, but also seem to have a function in
supporting and regulating ‘stemness’ and early cell differentia-
tion, especially in the adjustment to environmental challenges.
The current amount of information regarding the expression
910 and role of drug transporters in human stem cells is relatively
limited, thus this unexplored territory of transporters may
rapidly expand in the near future.
7. Expert opinion
The protection of pluripotent stem cells and their differentiated
915 progenies against toxic environmental factors has an utmost
importance in early human development. Hydrophobic com-
pounds, including drugs and xenobiotics, in many cases rapidly
enter the lipophilic cell membranes, and specific membrane
transporter proteins are required to modulate the final cellular
920 drug levels, thus protecting our cells against these compounds.
 SLC transporters, sometimes denoted as ‘uptake transporters ’,
inmost cases facilitate the transcellular clearance of drugs, with a
number of variable transport mechanisms. In contrast, ABC 
transporter proteins work as ATP-dependent primary active
925drug extrusion pumps. All these drug and xenobiotic transpor-
ters are large transmembrane proteins which catalyse the move-
ment of a wide variety of chemicals with a relatively
promiscuous pattern of interactions.
In this review, we summarize and discuss the available data
930for the key ABC and SLC drug transporters which contribute to
the protection of undifferentiated human stem cells and the cells
during initial tissue differentiation. Many of these transporters
have a relatively low level of endogenous expression; therefore,
we present the major methodological problems and discuss
935some solutions for properly assessing transporter expression,
localization and function in stem cells. We demonstrate the
great challenge of properly analysing transporter expression
and function in the continuously changing forms of stem cells
between pluripotent and partially differentiated states. We espe-
940cially focus on the regulation of transporter expression by factors
modulating cell differentiation properties. In addition, we also
present available data for the function of drug transporters in
adjustment to environmental challenges.
Although some early studies had conflicting results due to
945methodically questionable measurements, based on the cur-
rently available, data we can conclude that some of the ABC
transporters, especially the ABCG2 multidrug transporter,
have a key role in the protection of undifferentiated human
stem cells against toxic materials and stress conditions.
950In addition, numerous other ABC transporters are differ-
ently expressed and regulated during early stem cell differ-
entiation, which may have a functional consequence in the
drug sensitivity and other transport properties of these newly
generated cell types. We know much less about SLC trans-
955porter expression in pluripotent stem cells, while a larger
amount of information is available for the foetal and placen-
tal human tissues in this regard.
As a summary, the area of drug transporters and their role in
pluripotent stem cells is an as yet relatively unexplored terri-
960tory of cell biology. Altogether this research has a great poten-
tial to help our understanding of the complex responses of
stem cells to environmental challenges. Based on the current
surge of studying human embryonic and induced pluripotent
stem cells, we may expect a rapid expansion of this knowledge,
965which may also help us to understand the regulation and toxic
modulation of ‘stemness’ and early differentiation.
Article highlights. 
● The key drug transporters in human stem cell mem-
branes are ABC and SLC transporters.
970● Human pluripotent stem cells variably express mem-
brane drug transporters, which provide protection
against toxic compounds and environmental challenges.
● The ABCG2 protein may serve as a stem cell marker
and is a key protective transporter.
975● Methodological problems are crucial in properly deter-
mining stem cell transporter expression.
Apáti et al.
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● Drug transporter expression patterns significantly
depend on culturing conditions and early cell
differentiation.
This box summarizes key points contained in the article.
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